SCHEMBL23199933

SCHEMBL23199933

Cc1ccc(CN(C(=O)Nc2ccc(F)c(F)c2)C2CCCC2)s1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
UBE2M P61081 9/20 0.48
DCUN1D1 Q96GG9 9/20 0.48
ALDH1A1 P00352 1/20 0.47
TP53 P04637 3/20 0.47
SLC6A9 P48067 1/20 0.46
SLC6A5 Q9Y345 1/20 0.46
MCHR1 Q99705 2/20 0.44
MAPT P10636 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
LMNA P02545 1/20 0.42
KDM4E B2RXH2 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23199932 0.83 ALDH1A1 (0.67) UBE2MDCUN1D1ALDH1A1TP53MAPT
SCHEMBL23699954 0.83 SMN1; SMN2 (0.55) UBE2MDCUN1D1ALDH1A1TP53MAPT
SCHEMBL23200018 0.82 ALDH1A1 (0.72) UBE2MDCUN1D1ALDH1A1SLC6A9SLC6A5
SCHEMBL23199982 0.81 LMNA (0.55) UBE2MDCUN1D1ALDH1A1TP53SLC6A9
SCHEMBL23200116 0.81 UBE2M (0.46) UBE2MDCUN1D1ALDH1A1TP53SLC6A9
SCHEMBL23200060 0.77 UBE2M (0.67) UBE2MDCUN1D1ALDH1A1TP53SLC6A9
SCHEMBL23200140 0.76 ALDH1A1 (0.47) UBE2MDCUN1D1ALDH1A1TP53SLC6A9
SCHEMBL23200045 0.76 TP53 (0.53) UBE2MDCUN1D1ALDH1A1TP53MAPT
SCHEMBL23200112 0.75 POLB (0.56) UBE2MDCUN1D1ALDH1A1TP53SLC6A9
SCHEMBL23699904 0.75 DCUN1D1 (0.57) UBE2MDCUN1D1TP53SLC6A9SLC6A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3802503-A1 UREA DERIVATIVE MODULATORS OF TRYPTOPHAN CATABOLISM E-Therapeutics plc (GB) 2021-04-14 EP claimed
US-20210238139-A1 MODULATORS OF TRYPTOPHAN CATABOLISM E-THERAPEUTICS PLC (GB) 2021-08-05 US disclosed
US-20210238139-A1 MODULATORS OF TRYPTOPHAN CATABOLISM E-THERAPEUTICS PLC (GB) 2021-08-05 US disclosed
EP-3802503-A1 UREA DERIVATIVE MODULATORS OF TRYPTOPHAN CATABOLISM E-Therapeutics plc (GB) 2021-04-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238139-A1 MODULATORS OF TRYPTOPHAN CATABOLISM TPH1, KYNU, TPH2 UBE2M 3929/4885DCUN1D1 1039/4885ALDH1A1 606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.